Compound treatment with GLP1 and GIP modulators as well as CCK agonists are being targeted for their therapeutic potential in the treatment of obesity and diabetes [21, 22]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.